Richter transformation in the era of novel agents

Wei Ding

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Recent approvals of several oral targeted agents have revolutionized chronic lymphocytic leukemia (CLL) therapy. However, CLL patients continue to progress; particularly, 4% to 20% of previously treated CLL patients undergo transformation into high-grade lymphoma. Richter transformation is defined as a transformation of CLL into aggressive lymphoma, most commonly diffuse large B-cell lymphoma. These patients typically have poor response to traditional chemotherapy used to treat de novo diffuse large B-cell lymphoma and similar or shorter overall survival (median 3-11 months) in the era of novel agents. Here, I review the contemporary literature on Richter transformation, particularly in the context of novel agents used in CLL, and discuss the management approach for these patients.

Original languageEnglish (US)
Pages (from-to)256-263
Number of pages8
JournalHematology (United States)
Issue number1
StatePublished - Nov 30 2018

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Richter transformation in the era of novel agents'. Together they form a unique fingerprint.

Cite this